Edwards Lifesciences Corp (EW) stock
EWNYSEOrthopedic, Prosthetic & Surgical Appliances & SuppliesFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 4, 2026Score 10/3040% above fair value
$92.01−2.43 (-2.57%)
Close on Oct 30, 2026Market cap $53.03BP/E 52.9Yield –
Earnings
Edwards Lifesciences's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.
Next report
Oct 29, 2026
Q3 FY2026 · estimated, after the close
Revenue, Q2 FY2026
$1.74B
+13.8% on a year earlier
adjusted EPS, Q2 FY2026
$0.78
$0.67 a year earlier
Latest guidance
Raised
Jul 23, 2026 · 12 items
Quarterly results
Revenue and earnings per share from each of Edwards Lifesciences's earnings releases, newest first
| Quarter | Reported | Revenue | YoY | EPS | Adj. EPS | Source |
|---|---|---|---|---|---|---|
| Q3 FY2026ended Sep 30, 2026 | Oct 29, 2026Expected | – | – | – | – | – |
| Q2 FY2026ended Jun 30, 2026 | Jul 23, 2026after the close | $1.74B | +13.8% | $0.42 | $0.78 | Release |
| Q1 FY2026ended Mar 31, 2026 | Apr 23, 2026after the close | $1.65B | +17.0% | $0.66 | $0.78 | Release |
| Q4 FY2025ended Dec 31, 2025 | Feb 10, 2026after the close | $1.57B | +12.9% | $0.11 | $0.58 | Release |
| Q3 FY2025ended Sep 30, 2025 | Oct 30, 2025after the close | $1.55B | +14.4% | $0.50 | $0.67 | Release |
| Q2 FY2025ended Jun 30, 2025 | Jul 24, 2025after the close | $1.53B | +10.4% | $0.57 | $0.67 | Release |
| Q1 FY2025ended Mar 31, 2025 | Apr 23, 2025after the close | $1.41B | -11.9% | $0.62 | $0.64 | Release |
| Q4 FY2024ended Dec 31, 2024 | Feb 11, 2025after the close | $1.39B | -9.2% | $0.58 | $0.59 | Release |
| Q3 FY2024ended Sep 30, 2024 | Oct 24, 2024after the close | $1.35B | -8.5% | $5.13 | $0.67 | Release |
| Q2 FY2024ended Jun 30, 2024 | Jul 24, 2024after the close | $1.39B | -9.4% | $0.61 | $0.70 | Release |
| Q1 FY2024ended Mar 31, 2024 | Apr 25, 2024after the close | $1.60B | +9.6% | $0.58 | $0.66 | Release |
| Q4 FY2023ended Dec 31, 2023 | Feb 6, 2024after the close | $1.53B | +13.3% | $0.61 | $0.64 | Release |
| Q3 FY2023ended Sep 30, 2023 | Oct 25, 2023after the close | $1.48B | +12.1% | $0.63 | $0.59 | Release |
| Q2 FY2023ended Jun 30, 2023 | Jul 26, 2023after the close | $1.53B | +11.7% | $0.50 | $0.66 | Release |
| Q1 FY2023ended Mar 31, 2023 | Apr 26, 2023after the close | $1.46B | +9.0% | $0.56 | $0.62 | Release |
| Q4 FY2022ended Dec 31, 2022 | Jan 31, 2023after the close | $1.35B | +1.5% | $0.65 | $0.64 | Release |
| Q3 FY2022ended Sep 30, 2022 | Oct 27, 2022after the close | $1.32B | +1.5% | $0.55 | $0.61 | Release |
| Q2 FY2022ended Jun 30, 2022 | Jul 28, 2022after the close | $1.37B | – | $0.65 | $0.63 | Release |
| Q1 FY2022ended Mar 31, 2022 | Apr 26, 2022after the close | $1.34B | – | $0.59 | $0.60 | Release |
| Q4 FY2021ended Dec 31, 2021 | Jan 26, 2022after the close | $1.33B | – | $0.53 | $0.51 | Release |
| Q3 FY2021ended Sep 30, 2021 | Oct 27, 2021after the close | $1.30B | – | $0.54 | $0.54 | Release |
| Q2 FY2021ended Jun 30, 2021 | Jul 29, 2021after the close | – | – | – | – | Filing |
| Q1 FY2021ended Mar 31, 2021 | Apr 20, 2021after the close | – | – | – | – | Filing |
| Q4 FY2020ended Dec 31, 2020 | Jan 27, 2021after the close | – | – | – | – | Filing |
| Q3 FY2020ended Sep 30, 2020 | Oct 22, 2020after the close | – | – | – | – | Filing |
| Q2 FY2020ended Jun 30, 2020 | Jul 23, 2020after the close | – | – | – | – | Filing |
Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.
Current guidance
Edwards Lifesciences's latest outlook for periods it has not reported yet, compared with what it said before
| Metric | Period | Guidance | Before | Change | Given |
|---|---|---|---|---|---|
| total sales | Q3 FY2026 | $1.63B – $1.71B | – | New | Jul 23, 2026 |
| adjusted EPSnon-GAAP | Q3 FY2026 | $0.71 – $0.77 | – | New | Jul 23, 2026 |
| TMTTnon-GAAP | FY2026 | $740.00M – $780.00M | – | New | Feb 10, 2026 |
| TMTT sales | FY2026 | $760.00M – $780.00M | $6.50B – $6.90B | Lowered | Jul 23, 2026 |
| total company constant currency sales growthnon-GAAP | FY2026 | +10% – +11% | +9% – +11% | Raised | Jul 23, 2026 |
| gross profit marginnon-GAAP | FY2026 | 78% – 79% | 78% – 79% | Reaffirmed | Jul 23, 2026 |
| operating profit marginnon-GAAP | FY2026 | 28% – 29% | – | New | Jul 23, 2026 |
| operating profit margin | FY2026 | 28% – 29% | – | New | Feb 10, 2026 |
| adjusted EPSnon-GAAP | FY2026 | $2.95 – $3.05 | $2.95 – $3.05 | Reaffirmed | Jul 23, 2026 |
| effective tax rate, excluding special itemsnon-GAAP | FY2026 | 16% – 19% | – | New | Jul 23, 2026 |
| R&D as a percentage of sales | FY2026 | 17% | – | New | Feb 10, 2026 |
| R&D expense as a percentage of sales | FY2026 | 17% | 17% | Reaffirmed | Jul 23, 2026 |
| TAVR sales | FY2026 | $4.70B – $5.00B | – | New | Apr 23, 2026 |
| TAVR sales growth | FY2026 | +7% – +9% | – | New | Apr 23, 2026 |
| TMTT sales | FY2026 | $740.00M – $780.00M | – | Lowered | Apr 23, 2026 |
Guidance vs results
The last range Edwards Lifesciences gave before each report, against the figure it then reported. Full years add up the four quarters.
| Period | Metric | Guidance | Actual | Result |
|---|---|---|---|---|
| Q2 FY2026 | adjusted EPS | $0.70 – $0.76 | $0.78 | Above range |
| Q2 FY2026 | Revenue | $1.66B – $1.74B | $1.74B | Above range |
| Q1 FY2026 | adjusted EPS | $0.70 – $0.76 | $0.78 | Above range |
| Q1 FY2026 | Revenue | $1.55B – $1.63B | $1.65B | Above range |
| FY2025 | adjusted EPS | $2.56 – $2.62 | $2.56Σ4Q | Within range |
| FY2025 | Revenue | $5.90B – $6.10B | $6.06BΣ4Q | Within range |
| FY2025 | Revenue growth | +10% | +5.75%Σ4Q | Below range |
| Q4 FY2025 | adjusted EPS | $0.58 – $0.64 | $0.58 | Within range |
| Q4 FY2025 | Revenue | $1.51B – $1.59B | $1.57B | Within range |
| Q3 FY2025 | adjusted EPS | $0.54 – $0.60 | $0.67 | Above range |
| Q3 FY2025 | Revenue | $1.46B – $1.54B | $1.55B | Above range |
| Q2 FY2025 | adjusted EPS | $0.59 – $0.65 | $0.67 | Above range |
| Q2 FY2025 | Revenue | $1.45B – $1.53B | $1.53B | Within range |
| Q1 FY2025 | adjusted EPS | $0.58 – $0.64 | $0.64 | Within range |
| Q1 FY2025 | Revenue | $1.35B – $1.43B | $1.41B | Within range |
| Q4 FY2024 | EPS | $0.53 – $0.57 | $0.59 | Above range |
| Q4 FY2024 | Revenue | $1.33B – $1.39B | $1.39B | Within range |
| Q3 FY2024 | EPS | $0.67 – $0.71 | $0.67 | Within range |
| Q3 FY2024 | Revenue | $1.56B – $1.64B | $1.35B | Below range |
| Q2 FY2024 | adjusted EPS | $0.67 – $0.71 | $0.70 | Within range |
| Q2 FY2024 | Revenue | $1.62B – $1.70B | $1.39B | Below range |
| Q1 FY2024 | adjusted EPS | $0.62 – $0.66 | $0.66 | Within range |
| Q1 FY2024 | Revenue | $1.53B – $1.61B | $1.60B | Within range |
| Q4 FY2023 | diluted earnings per share | $0.60 – $0.66 | $0.64 | Within range |
| Q4 FY2023 | Revenue | $1.45B – $1.53B | $1.53B | Within range |
| Q3 FY2023 | adjusted EPS | $0.55 – $0.61 | $0.59 | Within range |
| Q3 FY2023 | Revenue | $1.44B – $1.52B | $1.48B | Within range |
| Q2 FY2023 | adjusted EPS | $0.62 – $0.68 | $0.66 | Within range |
| Q2 FY2023 | Revenue | $1.48B – $1.56B | $1.53B | Within range |
| Q1 FY2023 | adjusted EPS | $0.58 – $0.64 | $0.62 | Within range |
| Q1 FY2023 | Revenue | $1.37B – $1.45B | $1.46B | Above range |
| Q3 FY2022 | adjusted EPS | $0.58 – $0.66 | $0.61 | Within range |
| Q3 FY2022 | Revenue | $1.30B – $1.37B | $1.32B | Within range |
| Q2 FY2022 | adjusted EPS | $0.61 – $0.69 | $0.63 | Within range |
| Q2 FY2022 | Revenue | $1.36B – $1.44B | $1.37B | Within range |
| Q1 FY2022 | adjusted EPS | $0.54 – $0.62 | $0.60 | Within range |
| Q1 FY2022 | Revenue | $1.27B – $1.35B | $1.34B | Within range |
| Q4 FY2021 | adjusted EPS | $0.53 – $0.59 | $0.51 | Below range |
| Q4 FY2021 | Revenue | $1.30B – $1.38B | $1.33B | Within range |
Guidance history
Every forecast Edwards Lifesciences put in an earnings release, newest first
| Given | Metric | Period | Guidance | Change |
|---|---|---|---|---|
| Jul 23, 2026 | adjusted EPS | FY2026 | $2.95 – $3.05 | Reaffirmed |
| Jul 23, 2026 | adjusted EPS | Q3 FY2026 | $0.71 – $0.77 | New |
| Jul 23, 2026 | gross profit margin | FY2026 | 78% – 79% | Reaffirmed |
| Jul 23, 2026 | operating profit margin | FY2026 | 28% – 29% | New |
| Jul 23, 2026 | R&D expense as a percentage of sales | FY2026 | 17% | Reaffirmed |
| Jul 23, 2026 | effective tax rate, excluding special items | FY2026 | 16% – 19% | New |
| Jul 23, 2026 | total company constant currency sales growth | FY2026 | +10% – +11% | Raised |
| Jul 23, 2026 | TAVR constant currency sales growth | FY2026 | +8% – +9% | Lowered |
| Jul 23, 2026 | TMTT sales | FY2026 | $760.00M – $780.00M | Lowered |
| Jul 23, 2026 | total company sales | FY2026 | $6.60B – $6.90B | Raised |
| Jul 23, 2026 | TAVR sales | FY2026 | $4.75B – $5.00B | Lowered |
| Jul 23, 2026 | total sales | Q3 FY2026 | $1.63B – $1.71B | New |
| Apr 23, 2026 | adjusted EPS | FY2026 | $2.95 – $3.05 | Raised |
| Apr 23, 2026 | adjusted EPS | Q2 FY2026 | $0.70 – $0.76 | New |
| Apr 23, 2026 | gross margin | FY2026 | 78% – 79% | Reaffirmed |
| Apr 23, 2026 | R&D expense as a percentage of sales | FY2026 | 17% | Reaffirmed |
| Apr 23, 2026 | TAVR sales growth | FY2026 | +7% – +9% | New |
| Apr 23, 2026 | TAVR sales | FY2026 | $4.70B – $5.00B | New |
| Apr 23, 2026 | TMTT sales | FY2026 | $740.00M – $780.00M | Lowered |
| Apr 23, 2026 | constant currency sales growth | FY2026 | +9% – +11% | Lowered |
| Apr 23, 2026 | total company sales | FY2026 | $6.50B – $6.90B | New |
| Apr 23, 2026 | total sales | Q2 FY2026 | $1.66B – $1.74B | New |
| Feb 10, 2026 | adjusted EPS | FY2026 | $2.90 – $3.05 | New |
| Feb 10, 2026 | adjusted EPS | Q1 FY2026 | $0.70 – $0.76 | New |
| Feb 10, 2026 | adjusted gross profit margin | FY2026 | 78% – 79% | New |
| Feb 10, 2026 | operating profit margin | FY2026 | 28% – 29% | New |
| Feb 10, 2026 | R&D as a percentage of sales | FY2026 | 17% | New |
| Feb 10, 2026 | constant currency sales growth | FY2026 | +8% – +10% | New |
| Feb 10, 2026 | TMTT growing | FY2026 | +35% – +45% | Raised |
| Feb 10, 2026 | TMTT | FY2026 | $740.00M – $780.00M | New |
| Feb 10, 2026 | total sales | Q1 FY2026 | $1.55B – $1.63B | New |
| Oct 30, 2025 | adjusted EPS | FY2025 | $2.56 – $2.62 | Raised |
| Oct 30, 2025 | adjusted EPS | Q4 FY2025 | $0.58 – $0.64 | New |
| Oct 30, 2025 | underlying growth rate guidance for TAVR | FY2025 | +7% – +8% | New |
| Oct 30, 2025 | total company sales growth | FY2025 | +10% | New |
| Oct 30, 2025 | total sales | Q4 FY2025 | $1.51B – $1.59B | New |
| Jul 24, 2025 | adjusted EPS | Q3 FY2025 | $0.54 – $0.60 | New |
| Jul 24, 2025 | adjusted EPS | FY2025 | $2.50 | New |
| Jul 24, 2025 | total company sales growth | FY2025 | +9% – +10% | New |
| Jul 24, 2025 | sales | FY2025 | $5.90B – $6.10B | New |
| Jul 24, 2025 | total sales | Q3 FY2025 | $1.46B – $1.54B | New |
| Apr 23, 2025 | adjusted EPS | Q2 FY2025 | $0.59 – $0.65 | New |
| Apr 23, 2025 | adjusted EPS | FY2025 | $2.40 – $2.50 | Reaffirmed |
| Apr 23, 2025 | operating margin | FY2025 | 27% – 28% | New |
| Apr 23, 2025 | total sales | Q2 FY2025 | $1.45B – $1.53B | New |
| Apr 23, 2025 | Edwards sales growth | FY2025 | +8% – +10% | New |
| Apr 23, 2025 | TMTT sales | FY2025 | $530.00M – $550.00M | New |
| Apr 23, 2025 | total company sales | FY2025 | $5.70B – $6.10B | Raised |
| Feb 11, 2025 | adjusted EPS | Q1 FY2025 | $0.58 – $0.64 | New |
| Feb 11, 2025 | adjusted EPS | FY2025 | $2.40 – $2.50 | New |
| Feb 11, 2025 | adjusted gross profit margin | FY2025 | 78% – 79% | New |
| Feb 11, 2025 | adjusted operating margins | FY2025 | 27% – 28% | New |
| Feb 11, 2025 | constant currency sales growth | FY2025 | +8% – +10% | New |
| Feb 11, 2025 | total sales | Q1 FY2025 | $1.35B – $1.43B | New |
| Oct 24, 2024 | EPS | Q4 FY2024 | $0.53 – $0.57 | New |
| Oct 24, 2024 | gross margin | FY2024 | 76% – 78% | New |
| Oct 24, 2024 | gross margin | Q4 FY2024 | 78% | New |
| Oct 24, 2024 | sales growth | FY2024 | +8% – +10% | Reaffirmed |
| Oct 24, 2024 | sales | Q4 FY2024 | $1.33B – $1.39B | New |
| Jul 24, 2024 | EPS | Q3 FY2024 | $0.67 – $0.71 | New |
| Jul 24, 2024 | sales | Q3 FY2024 | $1.56B – $1.64B | New |
| Jul 24, 2024 | Edwards sales growth | FY2024 | +8% – +10% | New |
| Apr 25, 2024 | adjusted EPS | Q2 FY2024 | $0.67 – $0.71 | New |
| Apr 25, 2024 | adjusted earnings per share | FY2024 | $2.70 – $2.80 | Reaffirmed |
| Apr 25, 2024 | total sales | Q2 FY2024 | $1.62B – $1.70B | New |
| Apr 25, 2024 | sales | FY2024 | $6.30B – $6.60B | New |
| Feb 6, 2024 | adjusted EPS | Q1 FY2024 | $0.62 – $0.66 | New |
| Feb 6, 2024 | adjusted earnings per share | FY2024 | $2.70 – $2.80 | New |
| Feb 6, 2024 | total sales | Q1 FY2024 | $1.53B – $1.61B | New |
| Feb 6, 2024 | sales | FY2024 | $6.30B – $6.60B | New |
| Oct 25, 2023 | diluted earnings per share | Q4 FY2023 | $0.60 – $0.66 | New |
| Oct 25, 2023 | adjusted earnings per share | FY2023 | $2.50 – $2.60 | Reaffirmed |
| Oct 25, 2023 | total sales | Q4 FY2023 | $1.45B – $1.53B | New |
| Oct 25, 2023 | constant currency sales growth | FY2023 | +10% – +13% | Reaffirmed |
| Jul 26, 2023 | adjusted EPS | Q3 FY2023 | $0.55 – $0.61 | New |
| Jul 26, 2023 | adjusted earnings per share | FY2023 | $2.50 – $2.60 | Raised |
| Jul 26, 2023 | total sales | Q3 FY2023 | $1.44B – $1.52B | New |
| Jul 26, 2023 | total company sales growth | FY2023 | +10% – +13% | Raised |
| Jul 26, 2023 | sales | FY2023 | $5.90B – $6.10B | Raised |
| Apr 26, 2023 | adjusted EPS | Q2 FY2023 | $0.62 – $0.68 | New |
| Apr 26, 2023 | adjusted earnings per share | FY2023 | $2.48 – $2.60 | Raised |
| Apr 26, 2023 | total sales | Q2 FY2023 | $1.48B – $1.56B | New |
| Apr 26, 2023 | sales | FY2023 | +10% – +12% | New |
| Apr 26, 2023 | sales | FY2023 | $5.60B – $6.00B | New |
| Jan 31, 2023 | adjusted EPS | Q1 FY2023 | $0.58 – $0.64 | New |
| Jan 31, 2023 | adjusted earnings per share | FY2023 | $2.45 – $2.60 | New |
| Jan 31, 2023 | total sales | Q1 FY2023 | $1.37B – $1.45B | New |
| Jan 31, 2023 | sales | FY2023 | $5.60B – $6.00B | New |
| Oct 27, 2022 | adjusted EPS | FY2022 | $2.40 – $2.50 | Lowered |
| Oct 27, 2022 | total company sales | FY2022 | $5.35B – $5.55B | Reaffirmed |
| Jul 28, 2022 | adjusted EPS | Q3 FY2022 | $0.58 – $0.66 | New |
| Jul 28, 2022 | adjusted EPS | FY2022 | $2.50 – $2.65 | Reaffirmed |
| Jul 28, 2022 | total sales | Q3 FY2022 | $1.30B – $1.37B | New |
| Jul 28, 2022 | underlying sales growth | FY2022 | +10% | New |
| Jul 28, 2022 | sales | FY2022 | $5.35B – $5.55B | Lowered |
| Apr 26, 2022 | adjusted EPS | Q2 FY2022 | $0.61 – $0.69 | New |
| Apr 26, 2022 | adjusted earnings per share | FY2022 | $2.50 – $2.65 | Reaffirmed |
| Apr 26, 2022 | total sales | Q2 FY2022 | $1.36B – $1.44B | New |
| Apr 26, 2022 | sales | FY2022 | $5.50B – $6.00B | Reaffirmed |
| Jan 26, 2022 | adjusted EPS | Q1 FY2022 | $0.54 – $0.62 | New |
| Jan 26, 2022 | adjusted earnings per share | FY2022 | $2.50 – $2.65 | New |
| Jan 26, 2022 | total sales | Q1 FY2022 | $1.27B – $1.35B | New |
| Jan 26, 2022 | sales | FY2022 | $5.50B – $6.00B | New |
| Oct 27, 2021 | adjusted EPS | Q4 FY2021 | $0.53 – $0.59 | New |
| Oct 27, 2021 | adjusted earnings per share | FY2021 | $2.07 – $2.27 | New |
| Oct 27, 2021 | TAVR | Q4 FY2021 | $850.00M – $910.00M | New |
| Oct 27, 2021 | sales | Q4 FY2021 | $1.30B – $1.38B | New |
| Oct 27, 2021 | sales | FY2021 | $5.20B – $5.40B | New |
Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.
Press releases
Releases Edwards Lifesciences filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Update
- Results
- Results
- Update
- Update
- Results
- News
- Update
- Results
- Results
- Results
- Results
- Update
- Results